乳腺癌免疫组化检测在乳腺癌患者诊治中的意义分析

目的：探讨免疫组化检测在乳腺癌患者诊治中的价值。方法：随机选取2011年1月-2013年1月的68例经过空心穿刺活捡并病理确诊的乳腺癌患者为研究对象，均采用免疫组化检测ER、PR、P53、Bcl-2，全部采用CEF化疗方案治疗3个月后手术治疗，再运用免疫组化SP法检测化疗前后乳腺癌组织中以上指标的阳性表达率情况。结果：ER、PR化疗前后比较无统计学意义（P〉0．05）；而P53、Bcl-2比较有明显的差异性（P〈0．05）；ER、PR的阴性和阳性和疗效情况无明显差异性，而P53、Bcl-2的阴性和阳性表达和化疗的效果有明显的差异性，P〈0．05，具有统计学意义。结论：免疫组化检测中ER、PR对乳腺癌化疗前后无明显差异性，而化疗可通过抑制P53的表达来抑制乳腺癌增值并通过升高Bcl-2表达来调整肿瘤细胞分化。

The Analysis of Breast Cancer Immunohistochemistry Detection in Diagnosis and Treatment of Breast Cancer Patients

Objective： To investigate the value of immunohistochemistry detection in diagnosis and treatment of breast cancer patients. Methods： 68 cases of breast cancer patients admitted in our hospital between Jan. 2011 and Jan. 2013 and diagnosed by hollow needle biopsy and pathological diagnosis were selected randomly for our study. All of the patients received immunohistochemistry detection of ER, PR, P53 and Bcl-2. After 3 months＇ surgical treatment using CEF chemotherapy treatment, SP method of immunohistochemistry detection was used to detect the positive rate of breast cancer patients before and after the CEF chemotherapy treatment on the indexes above. Results： ER and PR had no significant difference before and after CEF chemotherapy treatment, but the comparison of P53 and Bcl-2 showed significant difference （P〈0.05）. The positive and negtive expression of ER and PR and chemotherapy efficacy had no significant difference, but the positive and negtive expression of P53 and Bcl-2 and the efficacy of CEF chemotherapy treatment showed significant difference （P〈0.05）, which was statistically significant. Conclusion： ER and PR detection in immunohistochemistry detection had no significant difference before and after the treatment of breast cancer patients. CEF chemotherapy treatment can inhibit breast cancer growth by inhibiting of P53 and can adjust the tumor cell diifferentiation by increasing the expression of Bcl-2.